Diabetes News and Research

Latest Diabetes News and Research

Entelos receives U.S. Patent for Predictive Toxicology for Biological Systems

Entelos, announced today that the U.S. Patent and Trademark Office has granted U.S. Patent No. 7,853,406 entitled "Predictive Toxicology for Biological Systems" to the Company.

9 Jan 2011

PCPs and kidney specialists favor collaborative care for progressive chronic kidney disease

Most primary care physicians (PCPs) and kidney specialists favor collaborative care for a patient with progressive chronic kidney disease (CKD), but their preferences on how and when to collaborate differ, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN). PCPs and kidney specialists need to partner more effectively to optimize care for patients with CKD.

7 Jan 2011

FDA approved KOMBIGLYZE XR for type 2 diabetes mellitus now available in pharmacies

Bristol-Myers Squibb Company, and AstraZeneca today announced that KOMBIGLYZE™ XR (saxagliptin and metformin HCl extended-release), approved by the U.S. Food and Drug Administration (FDA) on November 5, 2010, is now available by prescription in pharmacies across the United States.

7 Jan 2011

Sucampo, Takeda initiate dosing in third lubiprostone phase 3 trial for opioid-induced bowel dysfunction

Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals North America, Inc. today announced the dosing of the first patient in the third phase 3 clinical trial of lubiprostone for the treatment of opioid-induced bowel dysfunction (OBD) in subjects with chronic, non-cancer pain, excluding those taking methadone. The primary endpoint is an overall responder rate based on the change from baseline in the reported frequency of spontaneous bowel movements (SBMs).

7 Jan 2011

BIND Biosciences commences BIND-014 Phase 1 clinical trial in cancer

BIND Biosciences announced today that it has initiated a Phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of BIND-014 in cancer patients. BIND-014, the first product candidate to enter clinical evaluation from BIND's broad proprietary Medicinal Nanoengineering platform, is a targeted polymeric nanoparticle containing the cytotoxic agent, docetaxel.

7 Jan 2011

Lower co-payments help companies, workers save health-care costs

Companies can cut health-care costs - for themselves and for their workers - by lowering co-payments on prescription drugs while promoting disease management, according to a comprehensive, three-year study commissioned by the Florida Health Care Coalition (FHCC).

7 Jan 2011

Study examines link between media consumption, eating disorders among adolescent girls in Fiji

For parents wanting to reduce the negative influence of TV on their children, the first step is normally to switch off the television set. But a new study suggests that might not be enough. It turns out indirect media exposure, i.e., having friends who watch a lot of TV, might be even more damaging to a teenager's body image.

7 Jan 2011

TD2 and Oncoholdings partner to accelerate development of superior oncology agents

TGen Drug Development (TD2) and Oncoholdings Inc. announced today a partnership agreement that could lead to the prompt development of new anti-cancer agents.

7 Jan 2011

Regular blood test shows pre-diabetes risk factors, reduces treatment costs

A simpler form of testing individuals with risk factors for diabetes could improve diabetes prevention efforts by substantially increasing the number of individuals who complete testing and learn whether or not they are likely to develop diabetes.

7 Jan 2011

Ligand, Chiva Pharmaceuticals enter strategic relationship to develop multiple Ligand assets, technology

Ligand Pharmaceuticals Incorporated announced today that it has entered into a strategic relationship with Chiva Pharmaceuticals, to develop multiple Ligand assets and technology in China and potentially worldwide.

7 Jan 2011

Isis Pharmaceuticals announces addition of two new drugs to development pipeline

Isis Pharmaceuticals, announced today that it has added two new drugs to its development pipeline, ISIS-FGFR4Rx and ISIS-STAT3Rx.

7 Jan 2011

Liver transplant recipients develop PTMS, face high risk of cardiovascular disease

Researchers from Israel have determined that more than half of liver transplant recipients develop post-transplantation metabolic syndrome, placing them at greater risk for cardiovascular disease.

7 Jan 2011

Lexicon Pharmaceuticals announces clinical trial, mechanistic study results of LX4211

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced data from a recently completed clinical trial and mechanistic study of a solid oral dose formulation for LX4211, a dual inhibitor of sodium-glucose co-transporters 1 and 2 (SGLT1 and SGLT2).

6 Jan 2011

Californians can now access information about local healthcare providers using MyHealthResource

Realizing the New Year's resolution of "good health" could be just a click of the mouse away - even for Californians without adequate health insurance, thanks to a free, online resource from Californians for Patient Care. Using MyHealthResource, available at www.calpatientcare.org, Californians can access information about local healthcare providers that provide primary, dental, vision and mental healthcare services to the uninsured and underinsured.

6 Jan 2011

Pros and cons of weight loss surgery in men and women

Women who underwent gastric band surgery to lose weight reported significant improvements in urinary function and quality of life after the operation, according to research published in the January issue of the urology journal BJUI.

6 Jan 2011

FDA clears STI Medical Systems' ImageSense technology for use in colposcopy

STI Medical Systems, an industry leader in medical imaging systems and machine vision software, announced today that the U.S. Food and Drug Administration has given clearance to the Company's precedent-setting ImageSense technology for use in colposcopy.

6 Jan 2011

Scientists identify prognostic biomarker to treat patients with HCV

Scientists at Inserm and Institut Pasteur have performed biomarker discovery on patients being treated for chronic hepatitis C infection. Their work, published in The Journal of Clinical Investigation, demonstrates that the plasma levels of the protein IP-10 predict, prior to treatment initiation, the efficacy of treatment with pegylated-interferon and ribavirin.

6 Jan 2011

Regular eye exams are critical to prevent glaucoma

Glaucoma is the second leading cause of blindness, may strike without symptoms, is not preventable, but it is treatable. During National Glaucoma Awareness Month, The Minnesota Optometric Association (MOA) urges regular eye exams because early detection and treatment is critical to maintain healthy vision and protect the eyes from the effects of glaucoma and other potentially blinding diseases.

6 Jan 2011

Positive topline results from ZGN-433 Phase 1b study in obesity patients

Zafgen, a pharmaceutical company pioneering novel obesity therapeutics to help the body regain and sustain a lean, healthy state by targeting imbalances in fat metabolism, today announced positive topline results from its Phase 1b study of ZGN-433, a methionine aminopeptidase 2 inhibitor, for the treatment of severe obesity.

6 Jan 2011

Avaxia Biologics generates compelling pre-clinical data in animal models of IBD

Avaxia Biologics, Inc., a privately-held biotech company developing an innovative platform technology to deliver orally-active antibodies to the gastrointestinal tract, announced today that it has generated compelling pre-clinical data in animal models of inflammatory bowel disease.

6 Jan 2011

Diabetes News and Research

Latest Diabetes News and Research

Entelos receives U.S. Patent for Predictive Toxicology for Biological Systems

PCPs and kidney specialists favor collaborative care for progressive chronic kidney disease

FDA approved KOMBIGLYZE XR for type 2 diabetes mellitus now available in pharmacies

Sucampo, Takeda initiate dosing in third lubiprostone phase 3 trial for opioid-induced bowel dysfunction

BIND Biosciences commences BIND-014 Phase 1 clinical trial in cancer

Lower co-payments help companies, workers save health-care costs

Study examines link between media consumption, eating disorders among adolescent girls in Fiji

TD2 and Oncoholdings partner to accelerate development of superior oncology agents

Regular blood test shows pre-diabetes risk factors, reduces treatment costs

Ligand, Chiva Pharmaceuticals enter strategic relationship to develop multiple Ligand assets, technology

Isis Pharmaceuticals announces addition of two new drugs to development pipeline

Liver transplant recipients develop PTMS, face high risk of cardiovascular disease

Lexicon Pharmaceuticals announces clinical trial, mechanistic study results of LX4211

Californians can now access information about local healthcare providers using MyHealthResource

Pros and cons of weight loss surgery in men and women

FDA clears STI Medical Systems' ImageSense technology for use in colposcopy

Scientists identify prognostic biomarker to treat patients with HCV

Regular eye exams are critical to prevent glaucoma

Positive topline results from ZGN-433 Phase 1b study in obesity patients

Avaxia Biologics generates compelling pre-clinical data in animal models of IBD

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Diabetes News and Research

Latest Diabetes News and Research

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in